06:29:46 EST Sun 14 Dec 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - https://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  1251.00.02·0.02567.00.0283.92130.025  0.025  0.020.045  0.0115:47:05Nov 1315 min RT 2¢
TSX - T1251.00.02·0.02567.00.025+0.00525.012.0020.025  0.025  0.0250.045  0.0110:13:5115 min
NEO ATS - U 0.025+0.00525.012.0010.025  0.025  0.02510:13:5115 min
Omega - O 0.0224.0120.025  0.025  0.0215:47:0515 min
CX2 - H 0.025+0.00525.034.3130.025  0.025  0.02510:13:5115 min
CXD - D 0.020.81    Oct 2815 min
MatchNOW - M 0.020.42    Sep 11/2015 min
CS2 - S 0.020.42    Nov 1315 min

Recent Trades - Last 10 of 13
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:47:05S0.02 1007 TD Sec19 DesjardinsE
15:47:05O0.02 5,0001 Anonymous19 DesjardinsK
15:39:34M0.0250.0051380 National Bank2 RBCE
12:44:36S0.02 3007 TD Sec57 InteractiveE
10:51:36M0.0250.00540013 Instinet2 RBCE
10:13:51H0.0250.00530,00013 Instinet1 AnonymousK
10:13:51U0.0250.00512,00013 Instinet1 AnonymousK
10:13:51O0.0250.00519,0001 Anonymous1 AnonymousK
10:13:51T0.0250.00512,00013 Instinet9 BMO NesbittKL
10:06:28H0.0250.0054,00080 National Bank1 AnonymousK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-11-13 18:42C:APLI0.025SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-11-13 18:42C:APLI0.025SEDAR Interim MD & ASEDAR Interim MD & A
2025-11-13 17:21C:APLI0.025News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
2025-11-05 15:11C:APLI0.025News ReleaseAppili Therapeutics arranges $750,000 private placement
2025-10-22 07:20C:APLI0.03News ReleaseAppili Therapeutics to Attend BARDA Innovation Symposium 2025
2025-10-01 17:08C:APLI0.04News ReleaseAppili, Vitalex win up to $40M (U.S.) VXV-01 contract
2025-09-23 20:42C:APLI0.02News ReleaseAppili Therapeutics holders approve AGM resolutions
2025-09-09 07:20C:APLI0.015News ReleaseAppili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
2025-08-14 17:31C:APLI0.015SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-08-14 17:31C:APLI0.015SEDAR Interim MD & ASEDAR Interim MD & A
2025-08-14 17:05C:APLI0.015News ReleaseAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
2025-08-06 17:16C:APLI0.015News ReleaseAppili releases tularemia vaccine results
2025-06-25 20:49C:APLI0.015SEDAR Annual Information FormSEDAR Annual Information Form
2025-06-25 20:39C:APLI0.015SEDAR MD & ASEDAR MD & A
2025-06-25 20:26C:APLI0.015SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-06-25 18:04C:APLI0.015News ReleaseAppili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
2025-05-30 16:19C:APLI0.015News ReleaseAppili terminates arrangement with Aditxt
2025-05-20 02:24C:APLI0.03News ReleaseAppili to receive termination fee from Aditxt
2025-05-01 07:34C:APLI0.03News ReleaseAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
2025-04-28 17:47C:APLI0.03News ReleaseAppili Therapeutics granted patents in U.S., Mexico